Vascular News and Research

RSS

Tongue piercing can result in serious injury: Research

First, your child gets her tongue pierced. Then, as if you needed something else, she starts "playing" with the tiny barbell-shaped stud, pushing it against her upper front teeth. And before you know it, she forces a gap between those teeth -- a fraction-of-an-inch gap that may cost thousands of dollars in orthodontic bills to straighten.

3 Aug 2010

Cardioxyl Pharmaceuticals achieves positive results in first clinical study of CXL-1020 for ADHF

Cardioxyl Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel therapeutic agents for the treatment of cardiovascular disease, today announced that it has achieved positive safety and tolerability results in the first clinical study of its lead drug candidate, CXL-1020, for the treatment of patients with acute decompensated heart failure. Each year in the United States, more than one million patients are hospitalized with acute heart failure.

2 Aug 2010

Thymosin beta 4 is essential to healthy heart development, embryonic survival: Research

RegeneRx Biopharmaceuticals, Inc. today announced that a research team from the Molecular Medicine Unit at UCL-Institute of Child Health in London reported preclinical findings that Thymosin beta 4, is essential to healthy heart development and embryonic survival.

2 Aug 2010

Scientists identify way to regulate uncontrolled growth of blood vessels

Researchers at the University of California, San Diego School of Medicine have identified a new way to regulate the uncontrolled growth of blood vessels, a major problem in a broad range of diseases and conditions.

2 Aug 2010

Researchers receive $4.7M contract to develop drugs to improve soldiers' performance at high altitude

Jonathan Stamler, MD, Director of the Institute for Transformative Molecular Medicine and the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at the Case Western Reserve University and University Hospitals Harrington-McLaughlin Heart & Vascular Institute, has recently received a $4.7 million contract from the Defense Advanced Research Projects Agency to fund the development of a new class of drugs that will selectively dilate blood cells under hypoxia (lack of oxygen in the body's tissues) and thereby enhance soldiers' performance at high altitude.

31 Jul 2010

Study shows estrogen stabilization may protect women from brain aneurysms risk

Results from a retrospective, case-control study presented today at the Society of NeuroInterventional Surgery (SNIS) 7th Annual Meeting could have significant implications for women at risk of brain aneurysms as data shows that oral contraceptives (OC) and hormone replacement therapy (HRT) may yield the additional benefit of protecting against the formation and/or rupture of brain aneurysms – balloon-like sacks that form in a weakened artery wall and, upon bursting, can cause severe disability or death.

31 Jul 2010

Opportunity in European embolization coil market leads to major acquisitions in 2010: MRG

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, high market opportunity in the European embolization coil market has led to several major acquisitions in 2010. The European market alone was valued at approximately $100 million in 2009, making successful niche competitors in this market attractive acquisition targets.

30 Jul 2010

Volcano second-quarter revenues increase 36% to record $73.5 million

Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that revenues in the second quarter of 2010 increased 36 percent versus revenues in the second quarter of 2009.

30 Jul 2010

FDA clears Hotspur's new balloon dilatation and embolectomy catheters

Hotspur Technologies, Inc. announced today that it has received FDA clearance for the first three commercial products in its portfolio. These products are based on Hotspur's unique and groundbreaking technology that makes dialysis access interventional and peripheral vascular procedures that open blood vessels less expensive, more efficient, and less invasive for patients.

30 Jul 2010

CryoLife second-quarter revenues increase 4% to record $29.3 million

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, announced today its results for the second quarter of 2010. Revenues for the second quarter increased 4 percent to a second quarter record of $29.3 million compared to $28.2 million for the second quarter of 2009. Net income for the second quarter of 2010 was $2.9 million, or $0.10 per basic and fully diluted common share, compared to $2.5 million, or $0.09 per basic and fully diluted common share, for the second quarter of 2009.

30 Jul 2010

Supplementation of vitamin D protects vascular systems: Study

Vitamin D deficiency is associated with arterial stiffness, a risk factor for heart disease and stroke, in black teens according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). Black teens taking vitamin D supplementation of 2,000 international units (IU) per day had a decrease in central arterial stiffness.

30 Jul 2010

New study shows vitamin D deficiency is associated with arterial stiffness

Vitamin D deficiency is associated with arterial stiffness, a risk factor for heart disease and stroke, in black teens according to a new study accepted for publication in The Endocrine Society's www.endo-society.org. Black teens taking vitamin D supplementation of 2,000 international units per day had a decrease in central arterial stiffness.

29 Jul 2010

Safeguard Scientifics second-quarter aggregate revenue of partner companies increase 47% to $91.6 million

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended June 30, 2010 was $91.6 million, up 47% from $62.3 million for the same partner companies in the same period of 2009. For the six months ended June 30, 2010, the aggregate partner company revenue was $176.9 million, up 45% from $121.8 million for the same partner companies for the same period of 2009.

29 Jul 2010

Covidien third-quarter 2010 net sales increase 2% to $2.56 billion

Covidien plc today reported results for the third quarter of fiscal 2010 (April - June 2010). Third-quarter net sales of $2.56 billion increased 2% from the $2.52 billion reported a year ago, with foreign exchange rate movement having no impact on the quarterly sales growth rate.

29 Jul 2010

Devax's AXXESS Biolimus A9 Eluting Coronary Bifurcation Stent System receives CE Mark approval

Devax, Inc. announced today the company received CE Mark for its AXXESS™ Biolimus A9® Eluting Coronary Bifurcation Stent System, allowing the company to initiate sales in the European Union and other countries that recognize the CE Mark.

29 Jul 2010

SIR offers five-day course that covers all aspects of acute stroke management

Catheter Lysis of Thromboembolic Stroke -an intensive five-day course offered by the Society of Interventional Radiology Oct. 24-28 in Dallas, Texas-provides interventional radiologists, neurointerventionalists, vascular neurologists and fellows-in-training with the unique educational opportunity to review, observe and discuss all aspects of acute stroke management.

29 Jul 2010

Positive results from phase I clinical trial of MultiStem in patients with AMI announced

Angiotech Pharmaceuticals, Inc. and partner Athersys, Inc. announced positive results from its phase I clinical trial of MultiStem, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction, more commonly referred to as a heart attack.

29 Jul 2010

LeMaitre Vascular second-quarter sales increase 12% $14.2mm

LeMaitre Vascular, Inc., a provider of peripheral vascular devices and implants, today announced Q2 2010 financial results. The Company posted record quarterly sales of $14.2mm and record quarterly operating income of $2.0mm. The Company also increased its share repurchase program to $5mm and raised its sales and operating income guidance for 2010.

29 Jul 2010

Researchers establish new criteria for liver transplantation

Researchers at the University of California, San Francisco propose that treatments used on liver cancers beyond the established Milan criteria for liver transplantation may be appropriate for all patients with hepatocellular carcinoma who are listed for transplantation. Full details appear in the August issue of Liver Transplantation, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

28 Jul 2010

Spectranetics second-quarter revenue increases 3% to $30.0 million

Spectranetics Corporation today reported financial results for the three and six months ended June 30, 2010.

28 Jul 2010

Vascular News and Research

Tongue piercing can result in serious injury: Research

Cardioxyl Pharmaceuticals achieves positive results in first clinical study of CXL-1020 for ADHF

Thymosin beta 4 is essential to healthy heart development, embryonic survival: Research

Scientists identify way to regulate uncontrolled growth of blood vessels

Researchers receive $4.7M contract to develop drugs to improve soldiers' performance at high altitude

Study shows estrogen stabilization may protect women from brain aneurysms risk

Opportunity in European embolization coil market leads to major acquisitions in 2010: MRG

Volcano second-quarter revenues increase 36% to record $73.5 million

FDA clears Hotspur's new balloon dilatation and embolectomy catheters

CryoLife second-quarter revenues increase 4% to record $29.3 million

Supplementation of vitamin D protects vascular systems: Study

New study shows vitamin D deficiency is associated with arterial stiffness

Safeguard Scientifics second-quarter aggregate revenue of partner companies increase 47% to $91.6 million

Covidien third-quarter 2010 net sales increase 2% to $2.56 billion

Devax's AXXESS Biolimus A9 Eluting Coronary Bifurcation Stent System receives CE Mark approval

SIR offers five-day course that covers all aspects of acute stroke management

Positive results from phase I clinical trial of MultiStem in patients with AMI announced

LeMaitre Vascular second-quarter sales increase 12% $14.2mm

Researchers establish new criteria for liver transplantation

Spectranetics second-quarter revenue increases 3% to $30.0 million

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News